Ertiprotafib | PTP-112 | CAS#251303-04-5

MedKoo Cat#: 319592 | Name: Ertiprotafib

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ertiprotafib, also known as PTP-112, is a Protein Tyrosine Phosphatase 1B Inhibitor (PTP1B inhibitor). Ertiprotafib normalized the plasma glucose and insulin levels in diabetic animal models, and progressed to a phase II clinical trial. Ertiprotafib is potentially useful for the treatment of Non-Insulin Dependent Diabetes. Ertiprotafib improves glycemic control and lowers lipids via multiple mechanisms. Ertiprotafib is also a potent inhibitor of IkappaB kinase beta (IKK-beta), with an IC(50) of 400nM.

Chemical Structure

Ertiprotafib

CAS#251303-04-5

Theoretical Analysis

MedKoo Cat#: 319592

Name: Ertiprotafib

CAS#: 251303-04-5

Chemical Formula: C31H27BrO3S

Exact Mass: 558.0864

Molecular Weight: 559.52

Elemental Analysis: C, 66.55; H, 4.86; Br, 14.28; O, 8.58; S, 5.73

Price and Availability

Size	Price	Availability
2mg	USD 150.00	Ready to ship
5mg	USD 250.00	Ready to ship
10mg	USD 450.00	Ready to ship
25mg	USD 750.00	Ready to ship
50mg	USD 1,150.00	Ready to ship
100mg	USD 1,850.00	Ready to ship
200mg	USD 2,750.00	Ready to ship
500mg	USD 4,350.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

PTP-112; PTP112; PTP 112; Ertiprotafib.

IUPAC/Chemical Name

(2R)-2-(4-(9-bromo-2,3-dimethylnaphtho(2,3-b)thiophen-4-yl)-2,6-dimethylphenoxy)-3-phenylpropionic acid

InChi Key

FONCZICQWCUXEB-RUZDIDTESA-N

InChi Code

InChI=1S/C31H27BrO3S/c1-17-14-22(15-18(2)29(17)35-25(31(33)34)16-21-10-6-5-7-11-21)27-23-12-8-9-13-24(23)28(32)30-26(27)19(3)20(4)36-30/h5-15,25H,16H2,1-4H3,(H,33,34)/t25-/m1/s1

SMILES Code

O=C(O)[C@H](OC1=C(C)C=C(C2=C(C(C)=C(C)S3)C3=C(Br)C4=CC=CC=C24)C=C1C)CC5=CC=CC=C5

Appearance

Light yellow solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Certificate of Analysis

View CoA: current batch, Lot#HOL60801

QC Data

View QC data: current batch, Lot#HOL60801

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 559.52 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Erbe DV, Wang S, Zhang YL, Harding K, Kung L, Tam M, Stolz L, Xing Y, Furey S, Qadri A, Klaman LD, Tobin JF. Ertiprotafib improves glycemic control and lowers lipids via multiple mechanisms. Mol Pharmacol. 2005 Jan;67(1):69-77. doi: 10.1124/mol.104.005553. Epub 2004 Oct 8. PMID: 15475571. 2: Kumar GS, Page R, Peti W. The mode of action of the Protein tyrosine phosphatase 1B inhibitor Ertiprotafib. PLoS One. 2020 Oct 2;15(10):e0240044. doi: 10.1371/journal.pone.0240044. PMID: 33007022; PMCID: PMC7531832. 3: Shrestha S, Bhattarai BR, Cho H, Choi JK, Cho H. PTP1B inhibitor Ertiprotafib is also a potent inhibitor of IkappaB kinase beta (IKK-beta). Bioorg Med Chem Lett. 2007 May 15;17(10):2728-30. doi: 10.1016/j.bmcl.2007.03.001. Epub 2007 Mar 3. PMID: 17407812. 4: Liu JZ, Zhang SE, Nie F, Yang Y, Tang YB, Yin W, Tian JY, Ye F, Xiao Z. Discovery of novel PTP1B inhibitors via pharmacophore-oriented scaffold hopping from Ertiprotafib. Bioorg Med Chem Lett. 2013 Dec 1;23(23):6217-22. doi: 10.1016/j.bmcl.2013.10.002. Epub 2013 Oct 8. PMID: 24148325. 5: Tong Z, Chandrasekaran A, Jordan R, Markiewicz V, Li H, Xiang Q, Shen L, Scatina J. Effects of ertiprotafib on hepatic cytochrome P450 and peroxisomal enzymes in rats and dogs, and in rat and human primary hepatocytes. Xenobiotica. 2007 Jan;37(1):1-18. doi: 10.1080/00498250600965115. PMID: 17178630. 6: Liu Z, Gao H, Zhao Z, Huang M, Wang S, Zhan J. Status of research on natural protein tyrosine phosphatase 1B inhibitors as potential antidiabetic agents: Update. Biomed Pharmacother. 2023 Jan;157:113990. doi: 10.1016/j.biopha.2022.113990. Epub 2022 Nov 29. PMID: 36459712. 7: Khator R, Biharee A, Bhatia N, Kulkarni S, Singh Y, Karthikeyan C, Jain AK, Thareja S. Medicinal Aspects of PTP 1B Inhibitors as Anti-Breast Cancer Agents: An Overview. Curr Med Chem. 2023 Sep 14. doi: 10.2174/0929867331666230914103645. Epub ahead of print. PMID: 37711015. 8: Singh S, Singh Grewal A, Grover R, Sharma N, Chopra B, Kumar Dhingra A, Arora S, Redhu S, Lather V. Recent updates on development of protein-tyrosine phosphatase 1B inhibitors for treatment of diabetes, obesity and related disorders. Bioorg Chem. 2022 Apr;121:105626. doi: 10.1016/j.bioorg.2022.105626. Epub 2022 Feb 24. PMID: 35255350. 9: Devi B, Vasishta SS, Das B, Baidya ATK, Rampa RS, Mahapatra MK, Kumar R. Integrated use of ligand and structure-based virtual screening, molecular dynamics, free energy calculation and ADME prediction for the identification of potential PTP1B inhibitors. Mol Divers. 2023 Feb 6. doi: 10.1007/s11030-023-10608-8. Epub ahead of print. PMID: 36745307. 10: Otake K, Azukizawa S, Takahashi K, Fukui M, Shibabayashi M, Kamemoto H, Kasai M, Shirahase H. 2-Acyl-tetrahydroisoquinoline-3-carboxylic acids: lead compounds with triple actions, peroxisome proliferator-activated receptor α/γ agonist and protein-tyrosine phosphatase 1B inhibitory activities. Chem Pharm Bull (Tokyo). 2011;59(7):876-9. doi: 10.1248/cpb.59.876. PMID: 21720040.